The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

Pignata S;Scambia G;Lorusso D;De Giorgi U;Nicoletto MO;Lauria R;Mosconi AM;Sacco C;Omarini C;Tagliaferri P;Ferrandina G;Cinieri S;Savarese A;Valabrega G;Pisano C;Salutari V;Raspagliesi F;Kopf B;Cecere SC;Amadio G;Maltese G;Di Napoli M;Greggi S;Signoriello S;Daniele G;Sacco A;Losito S;Normanno N;Perrone F;Gallo C;Piccirillo MC;MITO Investigators.

2019-01-01